| Title |
Selecting an Antidepressant for Use in a Patient with Epilepsy
|
|---|---|
| Published in |
Drug Safety, November 2012
|
| DOI | 10.2165/00002018-199818020-00004 |
| Pubmed ID | |
| Authors |
Stephen Curran, Karel de Pauw |
| Abstract |
Depression is a common and disabling condition and is especially disabling for patients who also have epilepsy. Antidepressants, particularly the tricyclic antidepressants are well known to be associated with seizure activity, but this is a very neglected area of research. Most of the data on the proconvulsive effects of antidepressants come from either work in animal models or from research into the effects of antidepressants in overdose. Both of these situations may tell us little about the behaviour of antidepressants in patients with epilepsy. The selective serotonin [5-hydroxytryptamine; 5-HT] reuptake inhibitors have a low seizure propensity, are well tolerated in overdose and have a favourable adverse effect profile, making them suitable as first line treatments for depression in patients with epilepsy. Other antidepressants, e.g. trazodone, moclobemide, mirtazepine, are also likely to have minimal proconvulsive effects, but adverse effects, interactions with other drugs, especially anticonvulsants, or the lack of clinical data may make their use less attractive. Although this review has focused on these clinically important issues it is clear that considerably more research needs to be undertaken on the seizure propensity and clinical efficacy of antidepressants in patients with epilepsy. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 23% |
| Student > Master | 2 | 15% |
| Researcher | 2 | 15% |
| Student > Bachelor | 1 | 8% |
| Lecturer > Senior Lecturer | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 3 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 15% |
| Agricultural and Biological Sciences | 1 | 8% |
| Nursing and Health Professions | 1 | 8% |
| Psychology | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 2 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2012.
All research outputs
#8,535,472
of 25,374,647 outputs
Outputs from Drug Safety
#916
of 1,852 outputs
Outputs of similar age
#86,230
of 285,568 outputs
Outputs of similar age from Drug Safety
#390
of 836 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,852 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,568 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 836 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.